Novo Nordisk says STEP Young phase 3 data show 40.4% BMI below threshold
Novo Nordisk announced first STEP Young phase 3 results for once-weekly semaglutide plus a reduced-calorie diet and increased physical activity in children aged 6 to under 12 with obesity.